Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Harrison Kenneth Ph.D. — OnKure Therapeutics, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Harrison Kenneth Ph.D.

Harrison Kenneth Ph.D.

Director at OnKure Therapeutics, Inc. · on record since May 26, 2021
Director at Edgewise Therapeutics, Inc. · on record since Mar 25, 2021

Insider trading activity of Harrison Kenneth Ph.D.

Transactions on record: 1; since Apr 12, 2021

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Apr 12, 2021

Figures computed from official regulatory filings — methodology.

Companies where Harrison Kenneth Ph.D. has traded

OnKure Therapeutics, Inc.1 tx · Apr 12, 2021

Track record of Harrison Kenneth Ph.D.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Harrison Kenneth Ph.D.

Co-insiders of Harrison Kenneth Ph.D.

Carruthers R MichaelEdgewise Therapeutics, Inc. +1
Novo A/SEdgewise Therapeutics, Inc. +1
Access Industries Holdings LLCOnKure Therapeutics, Inc.
ACCESS INDUSTRIES MANAGEMENT, LLCOnKure Therapeutics, Inc.
ACORN BIOVENTURES 2, L.P.OnKure Therapeutics, Inc.
ACORN BIOVENTURES, L.P.OnKure Therapeutics, Inc.
Acorn Capital Advisors GP 2, LLCOnKure Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

ACORN CAPITAL ADVISORS GP, LLCOnKure Therapeutics, Inc.

Agresta SamuelOnKure Therapeutics, Inc.

AI Biotechnology LLCOnKure Therapeutics, Inc.

BASKETT FORESTOnKure Therapeutics, Inc.

Blaustein RobertEdgewise Therapeutics, Inc.

Blavatnik LenOnKure Therapeutics, Inc.

Blunt Roshawn A.OnKure Therapeutics, Inc.

Brege LauraEdgewise Therapeutics, Inc.

Cardon LonOnKure Therapeutics, Inc.

Chen BihuaOnKure Therapeutics, Inc.

Cormorant Asset Management, LPOnKure Therapeutics, Inc.

Cormorant Global Healthcare Master Fund, LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund III LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund IV LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund V LPOnKure Therapeutics, Inc.

Cruse MichaelOnKure Therapeutics, Inc.

Derakhshan BehradEdgewise Therapeutics, Inc.

Donovan Joanne M.Edgewise Therapeutics, Inc.

Dorenbaum AlejandroOnKure Therapeutics, Inc.

Dube Eric MOnKure Therapeutics, Inc.

Edris BadreddinEdgewise Therapeutics, Inc.

FLESHER GREGORY J.OnKure Therapeutics, Inc.

Florence Anthony A. Jr.OnKure Therapeutics, Inc.

Fox Jonathan CEdgewise Therapeutics, Inc.

GREY MICHAEL GOnKure Therapeutics, Inc.

Hall AshleyOnKure Therapeutics, Inc.

Hartley DylanOnKure Therapeutics, Inc.

Hoelscher Paul W.OnKure Therapeutics, Inc.

Hove Anders DOnKure Therapeutics, Inc.

Jansen Valerie MalyvanhOnKure Therapeutics, Inc.

Jindal Vineet R.OnKure Therapeutics, Inc.

Johnson Wendy S.OnKure Therapeutics, Inc.

KOCH KEVINEdgewise Therapeutics, Inc.

Kordel JohanOnKure Therapeutics, Inc.

Lam JenniferOnKure Therapeutics, Inc.

Leonard Braden MichaelOnKure Therapeutics, Inc.

Leverone Jason A.OnKure Therapeutics, Inc.

Makhzoumi MohamadOnKure Therapeutics, Inc.

MAKOWER JOSHUAOnKure Therapeutics, Inc.

Manke IsaacOnKure Therapeutics, Inc.

Martin Christopher NathanEdgewise Therapeutics, Inc.

Mathers Edward TOnKure Therapeutics, Inc.

MOORE JOHN REdgewise Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
OnKure Therapeutics, Inc.	Apr 12, 2021	AwardD	14,000	0.00 USD	$0	SEC